Biogen

BIIB · NASDAQ

$243.10+$9.62 (+4.12%)TodayMarket closed · Oct 20, 7:52 PM ET

Prev close $233.48

Latest news

Press releaseOct 19, 7:30 AM ETGlobe Newswire
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
Press releaseOct 5, 7:00 AM ETBusiness Wire
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Press releaseOct 2, 11:20 AM ETGlobe Newswire
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
NewsSep 24, 1:35 PM ET
10 Health Care Stocks Whale Activity In Today’s Session
Press releaseSep 23, 4:01 PM ETBusiness Wire
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
Press releaseSep 17, 4:15 PM ETGlobe Newswire
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
Press releaseSep 16, 2:00 AM ETGlobe Newswire
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
Press releaseSep 8, 8:30 AM ETGlobe Newswire
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
Press releaseSep 3, 7:30 PM ETBusiness Wire
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Press releaseSep 3, 7:30 PM ETGlobe Newswire
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
NewsSep 3, 4:06 AM ET
Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment
Press releaseSep 3, 12:00 AM ETGlobe Newswire
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Press releaseSep 2, 8:00 AM ETBusiness Wire
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
Press releaseSep 1, 7:30 AM ETBusiness Wire
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Press releaseSep 1, 7:30 AM ETGlobe Newswire
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Press releaseAug 31, 7:30 PM ETGlobe Newswire
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
Press releaseAug 24, 8:04 AM ETGlobe Newswire
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
Press releaseAug 24, 8:00 AM ETPRNewswire
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
Press releaseAug 5, 8:00 AM ETBusiness Wire
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Press releaseAug 3, 4:01 PM ETBusiness Wire
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
NewsJul 29, 1:36 PM ETVandana Singh
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio
Press releaseJul 27, 4:01 PM ETBusiness Wire
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
Press releaseJul 16, 7:47 AM ETPRNewswire
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
Press releaseJul 15, 8:15 AM ETGlobe Newswire
Biogen Appoints Michael J. Parini as Chief Legal Officer
NewsJul 14, 11:49 AM ETVandana Singh
Why Is Biogen Stock Falling Tuesday?
Press releaseJul 14, 11:18 AM ETGlobe Newswire
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Press releaseJul 14, 11:15 AM ETPRNewswire
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Press releaseJul 14, 9:15 AM ETGlobe Newswire
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Press releaseJul 13, 5:38 PM ETGlobe Newswire
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
NewsJul 13, 2:23 PM ET
FDA Grants Approval For At-Home Starting Dose For Alzheimer's Treatment Leqembi
NewsJul 1, 4:27 PM ET
Biogen Expects $164M Q2 2026 And $290M-$320M Q3 2026 IPR&D And Milestone Charges, Impacting Earnings By $0.95 And $1.75–$1.95 Per Share, Respectively
NewsJun 29, 11:27 AM ETPriya Nigam
Biogen: Key Takeaways From Needham’s Meeting With Top Management
Press releaseMay 22, 9:00 AM ETPRNewswire
Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky
Press releaseMay 20, 9:00 AM ETGlobe Newswire
Levi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB)
Press releaseMay 14, 8:35 AM ETGlobe Newswire
Biogen Completes Acquisition of Apellis Pharmaceuticals
NewsMay 1, 2:30 AM ETSweta Killa
Tech Powers Nasdaq's Best Month Since 2020: These Stocks Are The Silent Performers
NewsApr 30, 11:57 AM ETAvi Kapoor
Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings
NewsApr 29, 7:11 AM ET
Earnings Scheduled For April 29, 2026
NewsApr 29, 6:06 AM ET
Biogen Q1 Adj. EPS $3.57 Beats $3.01 Estimate, Sales $2.478B Beat $2.255B Estimate
NewsDec 10, 8:44 AM ETAvi Kapoor
This Biogen Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

10 Health Care Stocks Whale Activity In Today’s Session

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease

LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

Biogen Appoints Michael J. Parini as Chief Legal Officer

Why Is Biogen Stock Falling Tuesday?

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

FDA Grants Approval For At-Home Starting Dose For Alzheimer's Treatment Leqembi

Biogen Expects $164M Q2 2026 And $290M-$320M Q3 2026 IPR&D And Milestone Charges, Impacting Earnings By $0.95 And $1.75–$1.95 Per Share, Respectively

Biogen: Key Takeaways From Needham’s Meeting With Top Management

Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky

Levi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB)

Biogen Completes Acquisition of Apellis Pharmaceuticals

Tech Powers Nasdaq's Best Month Since 2020: These Stocks Are The Silent Performers

Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings

Earnings Scheduled For April 29, 2026

Biogen Q1 Adj. EPS $3.57 Beats $3.01 Estimate, Sales $2.478B Beat $2.255B Estimate

This Biogen Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday